{
  "docId": "019de072-ece7-71de-8eba-0df52639d987",
  "docSlug": "f4caf3b83872d8591c78c133c07757ed",
  "documentTitle": "BenevolentAI | Investor Presentation Deck | 19 slides",
  "authorId": "benevolentai",
  "authorName": "BenevolentAI",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 19,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "Includes scientific data plots showing dose-dependent inhibition of TNF-a, IL-4, and CGRP.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-ece7-71de-8eba-0df52639d987/11",
  "deckHref": "/decks/019de072-ece7-71de-8eba-0df52639d987",
  "deckJsonHref": "/decks/019de072-ece7-71de-8eba-0df52639d987.json",
  "deckAnchorHref": "/decks/019de072-ece7-71de-8eba-0df52639d987#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.4,
        "x": 0.55,
        "y": 0.25
      },
      "kind": "chart",
      "text": "BEN-2293 Inhibition of human primary T-cell activation (TNFa and IL-4)",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6e64e854-67d2-45d4-a734-37063aff6936",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.3,
        "x": 0.55,
        "y": 0.6
      },
      "kind": "chart",
      "text": "BEN-2293 mediated inhibition of CGRP in DRG neurons",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7142dc7f-e998-4961-b82a-bab636de71b7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "list",
      "text": "BEN-2293 is highly selective for Trk receptors; dose dependently inhibits release of inflammatory Th1 and Th2 cytokines; inhibits release of CGRP; demonstrates excellent tolerability and safety margins.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2b867cad-a3af-4117-8a74-e1c023e6abd8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Key: Tropomyosin-related kinase (Trk) receptor tyrosine kinase family, namely TrkA, TrkB, and TrkC; Nerve Growth Factor (NGF); Brain Derived Neurotrophic Factor (BDNF); Neurotrophin-3 (NTF-3)/NT3",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "31be2f81-2750-449d-bcdf-5ef96eadb609",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "We expect BEN-2293 to provide both symptomatic relief and to reverse disease progression in atopic dermatitis",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9d2bdec3-3d45-4f74-9532-cd76c1a7b418",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 11,
      "from": 3,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "8b4989da-37eb-42d1-a462-8ea57fa882d7",
      "evidence": "Drug development is failing patients and BenevolentAI's solution",
      "position": 0,
      "objective": "Highlight the cost of inaction in drug development",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 15,
      "from": 10,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "b60aafe0-945b-4485-b373-af4183f36f2b",
      "evidence": "BEN-2293 and BEN-8744 progress",
      "position": 1,
      "objective": "Showcase quick wins and big bets in pipeline",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}